Tế bào T được chế tạo bằng mRNA chimeric antigen receptor (CAR) nhắm vào mesothelin kích thích hoạt động chống khối u trong các khối u rắn
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388
Brentjens, 2013, CD19-targeted t cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia, Sci Transl Med, 5, 177ra38, 10.1126/scitranslmed.3005930
Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134
Lamers, 2013, Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity, Mol Ther, 14, 904, 10.1038/mt.2013.17
Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J Clin Oncol, 24, e20, 10.1200/JCO.2006.05.9964
Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N Engl J Med, 365, 1673, 10.1056/NEJMoa1106152
Kalos, 2013, Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology, Immunity, 39, 49, 10.1016/j.immuni.2013.07.002
Argani, 2001, Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE), Clin Cancer Res, 7, 3862
Chang, 1996, Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers, Proc Natl Acad Sci U S A, 93, 136, 10.1073/pnas.93.1.136
Ho, 2005, Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients, Clin Cancer Res, 11, 3814, 10.1158/1078-0432.CCR-04-2304
Thomas, 2004, Mesothelin specific CD8+ T cell responses provide evidence of in vivo cross-priming by antigen presenting cells in vaccinated pancreatic cancer patients, J Exp Med, 200, 297, 10.1084/jem.20031435
Kelly, 2012, Mesothelin-targeted agents in clinical trials and in preclinical development, Mol Cancer Ther, 11, 517, 10.1158/1535-7163.MCT-11-0454
Hassan, 2013, Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression, Sci Transl Med, 5, 208ra147, 10.1126/scitranslmed.3006941
Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc Natl Acad Sci U S A, 106, 3360, 10.1073/pnas.0813101106
Zhao, 2010, Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor, Cancer Res, 70, 9062, 10.1158/0008-5472.CAN-10-2880
Barrett, 2011, Treatment of advanced leukemia in mice with mRNA engineered T cells, Hum Gene Ther, 22, 1575, 10.1089/hum.2011.070
Barrett, 2013, Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia, Hum Gene Ther, 24, 717, 10.1089/hum.2013.075
Kalos, 2011, T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia, Sci Transl Med, 3, 95ra73, 10.1126/scitranslmed.3002842
Maus, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunol Res.
Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood, 118, 6050, 10.1182/blood-2011-05-354449
John, 2013, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin Cancer Res, 19, 5636, 10.1158/1078-0432.CCR-13-0458
Hassan, 2007, Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers, Clin Cancer Res, 13, 5144, 10.1158/1078-0432.CCR-07-0869
Disis, 2011, Immunologic biomarkers as correlates of clinical response to cancer immunotherapy, Cancer Immunol Immunother, 60, 433, 10.1007/s00262-010-0960-8
Fonseca, 2009, Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction, Blood, 113, 1681, 10.1182/blood-2007-09-114157
Gnjatic, 2010, Seromic profiling of ovarian and pancreatic cancer, Proc Natl Acad Sci U S A, 107, 5088, 10.1073/pnas.0914213107
Marina, 2010, Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens, Cancer Res, 70, 1344, 10.1158/0008-5472.CAN-09-3143
Hall, 2005, Expression profiling the human septin gene family, J Pathol, 206, 269, 10.1002/path.1789
Oh, 1999, Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells, Nucleic Acids Res, 27, 4008, 10.1093/nar/27.20.4008